EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2021 | OneProjects | Series A | 8M |
5/2023 | VarmX | Series B | 0 |
1/2012 | Prosensa | Venture Round | 0 |
6/2007 | Kiadis Pharma | Venture Round | 0 |
2/2018 | Merus | Post-IPO Equity | 55.8M |
7/2021 | Xilis | Series A | 0 |
7/2020 | ViCentra | Venture Round | 0 |
9/2019 | Nkarta Therapeutics | Series B | 114M |
9/2012 | IlluminOss Medical | Series C | 0 |
11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
1/2017 | Binx Health | Series D | 0 |
3/2023 | QurAlis | Series B | 0 |
12/2015 | Xeltis | Series B | 3.3M |
7/2011 | Binx Health | Series B | 27.1M |
10/2013 | Merus | Series B | 42.2M |
3/2015 | Cardiac Dimensions | Equity | 15.2M |
9/2018 | Endotronix | Series D | 0 |
9/2020 | Cardiac Dimensions | Series C | 17.5M |
10/2008 | Cobalt Technologies | Series C | 0 |
4/2015 | Merus | Series C | 79.1M |
8/2021 | T-knife | Series B | 110M |
10/2021 | Egle Therapeutics | Series A | 0 |
3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
12/2021 | AviadoBio | Series A | 0 |
5/2012 | Celladon | Venture Round | 10M |
5/2017 | ImCheck Therapeutics | Series A | 21.9M |
5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
5/2003 | BioXell | Series B | 19.9M |
7/2020 | Vico Therapeutics | Series A | 31M |
3/2004 | 4-Antibody AG | Seed Round | 2.1M |
7/2014 | Mint Solutions | Series A | 6M |
11/2017 | Orphazyme | Post-IPO Equity | 0 |
8/2016 | Mint Solutions | Series B | 5.6M |
4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
4/2021 | Onward | Venture Round | 0 |
12/2019 | ImCheck Therapeutics | Series B | 53.2M |
8/2021 | Cardior Pharmaceuticals | Series B | 0 |
4/2014 | Binx Health | Series B | 0 |
3/2017 | Rainier Therapeutics | Series B | 30M |
7/2020 | VarmX | Series B | 36.3M |
11/2016 | OxThera | Series D | 34.1M |
1/2010 | Cellerix | Series C | 37.7M |
11/2009 | Cellerix | Series B | 40.5M |
9/2007 | Cellerix | Series B | 37.2M |
4/2023 | Evommune | Series B | 50M |
11/2021 | HotSpot Therapeutics | Series C | 0 |
1/2016 | Rainier Therapeutics | Series A | 13M |
1/2010 | Kreatech Diagnostics | Series B | 0 |
6/2011 | Mendor | Series B | 11.7M |
4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
9/2014 | Affimed | Series E | 0 |
1/2016 | ViCentra | Series B | 10.9M |
9/2016 | Immunic Therapeutics | Series A | 19.6M |
5/2020 | Arvelle Therapeutics | Series A | 0 |
8/2007 | FlowCardia | Series C | 0 |
1/2023 | Amolyt Pharma | Series C | 0 |
2/2010 | Promethera Biosciences | Series A | 7.3M |
11/2011 | Harvest Automation | Series B | 7.9M |
11/2003 | Affectis Pharmaceuticals | Series A | - |
8/2007 | Isto Technologies | Series E | 0 |
9/2021 | Amolyt Pharma | Series B | 0 |
4/2000 | NewBiotics | Venture Round | 6.3M |
5/2011 | Cobalt Technologies | Series D | 0 |
8/2018 | Artios Pharma | Series B | 0 |
10/2015 | Luxendo | Series A | 0 |
9/2019 | Pharvaris | Series B | 66M |
5/2019 | DNA Script | Series B | 38.5M |
1/2011 | Nexstim | Venture Round | 0 |
6/2009 | Pronota | Series B | 7.4M |
1/2009 | BMEYE | Series A | - |
2/2022 | Perfuze | Series A | 0 |
3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
6/2022 | ImCheck Therapeutics | Series C | 0 |
4/2004 | NewBiotics | Series E | 4.6M |
5/2016 | Nouscom | Series A | 13.6M |
11/2017 | Xeltis | Series C | 53M |
12/2007 | Vivendy Therapeutics | Series A | 15.4M |
7/2020 | Cybin | Series B | 0 |
11/2009 | Kreatech Diagnostics | Venture Round | 0 |
5/2008 | Asoyia | Venture Round | 4M |
7/2021 | Artios Pharma | Series C | 0 |
3/2010 | Seahorse Bioscience | Series D | 5M |
10/2015 | Sequana Medical | Series C | 0 |
8/2021 | Visus Therapeutics | Equity | 20M |
6/2020 | OneProjects | Series A | 12.4M |
1/2010 | Harvest Automation | Series A | 4M |
4/2014 | Heart Metabolics | Series A | 20M |
1/2007 | 4-Antibody AG | Series A | 18.4M |
10/2012 | Cobalt Technologies | Venture Round | 5M |
3/2019 | SNIPR Biome | Series A | 50M |
12/2014 | Xeltis | Series B | 33.5M |
4/2005 | DNage | Series A | 1.9M |
1/2016 | Pharvaris | Series A | 16.3M |
4/2006 | Pronota | Series A | 7.8M |
1/2010 | Merus | Series B | 0 |
4/2012 | Cobalt Technologies | Venture Round | 2.9M |
1/2005 | OctoPlus | Series B | 23.9M |
5/2018 | Rainier Therapeutics | Series B | 20M |
2/2007 | Prosensa | Series A | 18M |
9/2010 | Harvest Automation | Series A | 1.3M |
10/2013 | Harvest Automation | Series C | 11.8M |
5/2003 | Santarus | Series D | 51.4M |
7/2017 | Simplify Medical | Series B | 21M |
2/2018 | Simplify Medical | Series B | 23M |
3/2007 | Okairos | Series A | 9.6M |
12/2021 | ViCentra | Series C | 0 |
10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
9/2007 | Nexstim | Venture Round | 10.9M |
4/2016 | Onward | Series A | 29.5M |
10/1999 | Devgen | Series B | 24.7M |
1/2012 | Pronota | Series C | 4.8M |
1/2007 | Movetis | Series A | 63.8M |
2/2010 | arGEN-X | Series A | 4.5M |
2/2009 | ActoGeniX | Private Equity Round | 17.4M |
2/2007 | ActoGeniX | Venture Round | 26.1M |
7/2019 | AM Pharma | Series F | 130.1M |
1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
11/2012 | Kiadis Pharma | Venture Round | 0 |
7/2001 | NewBiotics | Series C | 0 |
9/2016 | Vivasure Medical | Series C | 18.3M |
9/2017 | Immunic Therapeutics | Series A | 11.9M |
2/2006 | EyeSense AG | Series A | 0 |
2/2023 | Xeltis | Series D | 0 |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
7/2002 | Scion Pharmaceuticals | Series B | 0 |
12/2006 | BMEYE | Series A | - |
7/2020 | DNA Script | Series B | 50M |
8/2006 | Pronota | Series A | 10.6M |
7/2003 | PamGene | Series B | 11.3M |
8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
5/2021 | Binx Health | Series E | 0 |
7/2019 | Amolyt Pharma | Series A | 0 |
6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
11/2014 | Curetis | Series B | 0 |
8/2007 | BioProcessors | Series C | 10M |
11/2009 | Vivoryon Therapeutics | Series B | 0 |
10/2021 | DNA Script | Series C | 0 |
1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
4/2007 | Affimed | Series B | 32M |
8/2016 | Rotation Medical | Series B | 12M |
12/2018 | XyloCor Therapeutics | Series A | 17M |
10/2012 | Affimed | Series D | 20.1M |
7/2014 | Rotation Medical | Series B | 27.2M |
12/2000 | PamGene | Series A | 6.2M |
12/2009 | Curetis | Series A | 27.9M |
2/2019 | Arvelle Therapeutics | Series A | 0 |
1/2021 | Neurent Medical | Series B | 0 |
7/2009 | Pasteuria Bioscience | Series B | 0 |
10/2007 | Syntaxin | Series B | 32M |
6/2015 | Neuravi | Series B | 21.5M |
3/2021 | XyloCor Therapeutics | Series A | 0 |
4/2023 | Evommune | Series B | 0 |
3/2023 | QurAlis | Series B | 0 |
2/2023 | Xeltis | Series D | 0 |
1/2023 | Amolyt Pharma | Series C | 0 |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
6/2022 | ImCheck Therapeutics | Series C | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
2/2022 | Perfuze | Series A | 0 |
12/2021 | ViCentra | Series C | 0 |
12/2021 | AviadoBio | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|